Clinical Milestone for Immix Biopharma as NXC-201 Data Chosen for Major Conference Immix Biopharma’s NXC-201 Phase 1/2 trial data, addressing relapsed/refractory AL Amyloidosis, has been selected for oral presentation at ASCO 2025. The therapy, which targets BCMA, has shown promising early results and holds both RMAT and Orphan Drug designations, underscoring its potential significance in hematologic malignancies.23